Expansion of collaboration for drug discovery

0

X-Chem, a privately held biotechnology company focused on the generation of novel small molecule therapeutics, entered an expanded global drug discovery collaboration with Bayer across multiple therapeutic areas and target classes. Under the terms of the agreement, Bayer will have expanded access to X-Chem’s DEX™ technology based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of the collaboration is to discover innovative lead structures for complex drug targets in areas of high unmet medical need.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here